APP mouse models for Alzheimer's disease preclinical studies.

Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC. · 2017

Read APP mouse models for Alzheimer's disease preclinical studies. by Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5579350.txt.

Introduction

Sasaguri and co-authors review mouse models of Alzheimer's disease in The EMBO Journal. Good animal models are vital for testing drugs before human trials. Many past drug candidates failed, and poor model choice is one suspect. The review focuses on mice built around the amyloid precursor protein gene.

First-generation mice overproduce that protein or its partner proteins. They show disease signs, but excess output can add traits that are not part of the disease. Second-generation mice carry human-like sequences in their own gene. They build up amyloid without the excess-output side effects. They still fall short of the full human disease. The authors weigh each model's strengths for a given study goal. Readers get a sober guide to picking the right mouse.

Catalog record

CREATORSasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE92 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5579350

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

APP mouse models for Alzheimer's disease preclinical studies By Hiroki Sasaguri, Per Nilsson, Shoko Hashimoto, Kenichi Nagata, Takashi Saito, Bart De Strooper, John Hardy, Robert Vassar, Bengt Winblad, Takaomi C Saido Published in: The EMBO Journal DOI: 10.15252/embj.201797397 ABSTRACT Abstract Animal models of human diseases that accurately recapitulate clinical pathology are indispensable for understanding molecular mechanisms and advancing preclinical studies. The Alzheimer's disease (AD) research community has historically used first‐generation transgenic (Tg) mouse models that overexpress proteins linked to familial AD (FAD), mutant amyloid precursor protein (APP), or APP and presenilin (PS). These mice exhibit AD pathology, but the overexpression paradigm may cause additional phenotypes unrelated to AD. Second‐generation mouse models contain humanized sequences and clinical mutations in the endogenous mouse App gene. These mice show Aβ accumulation without phenotypes related to overexpression but are not yet a clinical recapitulation of human AD. In this review, we evaluate different APP mouse models of AD, and review recent studies using the second‐generation mice. We advise AD researchers to consider the comparative strengths and limitations of each model against the scientific and therapeutic goal of a prospective preclinical study. MODELING PRECLINICAL AD WITH APP MICE Alzheimer's disease (AD) is the most common neurodegenerative disease. In 2015, of the ~47 million individuals with dementia worldwide (Prince et al, 2016), AD accounted for 50–70% of these cases (Winblad et al, 2016). In the coming decades, global AD prevalence is projected to reach higher epidemic levels that will place a massive economic burden on society. Given the grim epidemiological forecast, scientifically based strategies to prevent AD are urgently needed, as evidenced by the fact that in the previous two decades more than 400 medication candidates failed to reach the clinic (Mangialasche et al, 2010). This large‐scale failure by the pharmaceutical industry and biomedical research community can be attributed to many factors, including inappropriate choice of mouse models, wrong timing for therapeutic interventions, over‐reliance on inappropriate assays for translational studies, or lack of precise biomarkers, most of which center on efficacy and reproducibility in preclinical studies of which animal models were a critical component. In this review, we focus on the important roles that genetically engineered mouse models have contributed to AD mechanistic studies and preclinical drug development. Recently, new mouse models have been introduced to the community, and we will summarize the construction, characteristics, and merits and demerits of current AD mouse models to facilitate understanding of these tools for the design of future studies. In this aim, we will be guided by the principle that AD is a disease that should ideally be prevented in preclinical stages where a potential interventional window of at least 20 years exists before dementia clinically manifests (Funato et al, 1998; Bateman et al, 2012). Clinically, AD is characterized by early memory deficits followed by a decline in other cognitive functions (Scheltens et al, 2016; Winblad et al, 2016). The pathology of AD begins before overt cognitive symptoms and includes the accumulation of amyloid β peptide (Aβ) as extracellular plaques, hyper‐phosphorylated tau as intracellular neurofibrillary tangles (NFTs), and chronic neuroinflammation, followed by the loss of neuronal cells mainly in the cerebral cortex and hippocampus (Braak & Braak, 1991; Hyman et al, 2012). In parallel, a coordinated breakdown in vascular, astroglial, and oligodendrocytic responses demonstrates that AD is a systems disorder and the roles and interactions of different cell types in the decline of brain homeostasis and resultant dementia is a major research topic (De Strooper & Karran, 2016). Aβ pathology is initiated at least two decades before cortical tau pathology and the onset of clinical symptoms (Bateman et al, 2012; Maruyama et al, 2013). After disease onset, it is increasingly difficult to treat symptoms after postmitotic neurons start to degenerate (Fig 1) and finely tuned neuronal circuits and cognitive skills are not easily recovered at later stages. Thus, the development of accurate preclinical animal models of AD for studies of disease mechanisms and the development of medications for early prevention and treatment are considered vital research goals in accord with the global epidemiological status. [Figure: Cortical pathology, neurological symptoms, and APP mouse models of AD There are three neurological phases leading to the onset of AD and associated cortical pathology. The first phase is preclinical AD, where Aβ accumulates in cortex without neurological symptoms. The second phase is mild cognitive impairment (MCI), where tauopathy and neurodegeneration proceed with predementia symptoms. The third phase is AD, where neurodegeneration eliminates neurons and neuronal circuits in an irreversible manner with progressively serious symptoms of dementia. As models of preclinical AD, APP‐overexpressing mice or App knock‐in mice exhibit extensive Aβ pathology without tauopathy and neurodegeneration, for which there is a preventive window of approximately two decades. Modified from Ihara and Arai (2007). The pathology shown is from the cortex of a 9‐month‐old App NL‐G‐F/NL‐G‐F mouse. Blue: Aβ; red: microglia (Iba‐1); green: astrocyte (GFAP) (Saito et al, 2014).] Sporadic late‐onset AD (LOAD) accounts for more than 99% of all cases (Campion et al, 1999), and the ratio of LOAD patients to all AD patients continues to increase because aging is a primary risk factor aligned with aging of the world population. Early‐onset AD (EOAD), in contrast, is predominately familial and caused by mutations in genes that encode amyloid precursor protein (App), presenilin‐1 (PSEN1 or PS1) and presenilin‐2 (PS2). Proteolytic processing of APP by β‐secretase (β‐site APP cleaving enzyme 1 or BACE1) and γ‐secretase generates soluble Aβ fragments. γ‐Secretase is a protein complex composed of PS1 or PS2, nicastrin, Aph1 and presenilin enhancer 2 (PEN2). Most familial AD (FAD) mutations affect processivity of γ‐secretase resulting in the release of longer Aβ peptides and a shift in the relative ratios of the different peptides, including the Aβ42/Aβ40 ratio (Welander et al, 2009; Chávez‐Gutiérrez et al, 2012). Similarly, mutations in the App gene result in the production of longer Aβ peptides that aggregate more easily (Rosenberg et al, 2016). Interestingly, an App A673T mutation was claimed to reduce the risk of sporadic AD (SAD) and age‐related cognitive decline by decreasing the production of Aβ (Jonsson et al, 2012), although these findings require confirmation (Wang et al, 2015) and the mutation appears to affect the biophysical properties of Aβ peptides (Benilova et al, 2014; Maloney et al, 2014). The existence of familial mutations that directly affect Aβ production and influence AD risk is often cited as evidence that Aβ accumulation is central to AD pathogenesis (amyloid cascade hypothesis: Selkoe & Hardy, 2016). In general, Aβ and tau pathology in sporadic and familial cases are morphologically similar, rationalizing the use of mouse models with genetically engineered FAD mutations for understanding SAD. However, the extent to which these models actually reproduce SAD remains unknown. A critical factor to consider in developing and using mouse APP models is the potential mechanism of Aβ accumulation. In FAD, Aβ deposition is primarily caused by the increased production of Aβ>40 except for intra‐Aβ sequence mutations that alter its structural properties (Selkoe & Hardy, 2016) or the Swedish mutation that increases all Aβ species by increasing cleavage at the β‐site. Whether the Iceland mutation App A673T is protective by decreasing Aβ production (Jonsson et al, 2012) remains controversial. However, because Aβ degradation declines with aging

Read the complete text